Hodgkin's Lymphoma Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Hodgkin's Lymphoma Pipeline Insight 2025' report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Hodgkin's Lymphoma pipeline landscape. It covers the Hodgkin's Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hodgkin's Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Hodgkin's Lymphoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Hodgkin's Lymphoma Pipeline Outlook
Key Takeaways from the Hodgkin's Lymphoma Pipeline Report
In May 2025, Celgene announced a phase II study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma.
In May 2025, Hoffmann-La Roche conducted a Phase I/II study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB), glofitamab, administered by intravenous (IV) infusion as a single agent and in combination with obinutuzumab, following pre-treatment with a one-time, fixed dose of obinutuzumab.
In May 2025, Bristol-Myers Squibb organized a study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
DelveInsight's Hodgkin's Lymphoma Pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Hodgkin's Lymphoma treatment.
The leading Hodgkin's Lymphoma Companies such as Merck Sharp & Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics and others.
Promising Hodgkin's Lymphoma Pipeline Therapies such as HCD122, Resminostat (4SC-201), Ruxolitinib, AK105, ITF2357, Panobinostat, Obatoclax mesylate (GX15-070MS) and others.
Stay ahead with the most recent pipeline outlook for Hodgkin's Lymphoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Hodgkin's Lymphoma Treatment Drugs
Hodgkin's Lymphoma Emerging Drugs Profile
AFM 13: Affimed Therapeutics
AFM13 is a first-in-class innate cell engager (ICE®) that uniquely activates the innate immune system to destroy CD30-positive hematologic tumors. AFM13 induces specific and selective killing of CD30-positive tumor cells, leveraging the power of the innate immune system by engaging and activating natural killer (NK) cells and macrophages. AFM13 is most advanced ICE® clinical program and was evaluated as monotherapy in a Phase IIB trial in patients with relapsed/refractory peripheral T cell lymphoma (REDIRECT). The study achieved an ORR of 32.4% demonstrating anti-tumor activity with a DOR of 2.3 months and a well-managed safety profile. AFM13 is a tetravalent bispecific innate cell engager designed to act as a bridge between the innate immune cells and the tumor creating the necessary proximity for the innate immune cells to specifically destroy the tumor cells. Currently it is in Phase II stage of clinical trial evaluation to treat Hodgkin's Lymphoma.
AUR105 : Aurigene Oncology
AUR105 is a small molecule that acts by targeting protein arginine methyltransferase 5 (PRMT5). The drug candidate is also under development for other indications like solid tumor, non-Hodgkin lymphoma, leukemia or Hodgkin lymphoma. The drug candidate is administered through oral route. Currently the drug is being evaluated in Phase I for the treatment of Hodgkin's Lymphoma.
The Hodgkin's Lymphoma Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Hodgkin's Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hodgkin's Lymphoma Treatment.
Hodgkin's Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Hodgkin's Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hodgkin's Lymphoma market
Explore groundbreaking therapies and clinical trials in the Hodgkin's Lymphoma Pipeline. Access DelveInsight's detailed report now! @ New Hodgkin's Lymphoma Drugs
Hodgkin's Lymphoma Companies
Merck Sharp & Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics and others.
Hodgkin's Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
intravenous
Subcutaneous
Topical
Hodgkin's Lymphoma Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Unveil the future of Hodgkin's Lymphoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Hodgkin's Lymphoma Market Drivers and Barriers
Scope of the Hodgkin's Lymphoma Pipeline Report
Coverage- Global
Hodgkin's Lymphoma Companies- Merck Sharp & Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics and others.
Hodgkin's Lymphoma Pipeline Therapies- HCD122, Resminostat (4SC-201), Ruxolitinib, AK105, ITF2357, Panobinostat, Obatoclax mesylate (GX15-070MS) and others.
Hodgkin's Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Hodgkin's Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Hodgkin's Lymphoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Hodgkin's Lymphoma Companies, Key Products and Unmet Needs
Table of Contents
Introduction
Executive Summary
Hodgkin's Lymphoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Hodgkin's Lymphoma – DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Drug Name: Company Name
Drug profiles in the detailed report…..
Mid-Stage Products (Phase II)
AFM13: Affimed Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
AUR105 : Aurigene Oncology
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Hodgkin's Lymphoma Key Companies
Hodgkin's Lymphoma Key Products
Hodgkin's Lymphoma- Unmet Needs
Hodgkin's Lymphoma- Market Drivers and Barriers
Hodgkin's Lymphoma- Future Perspectives and Conclusion
Hodgkin's Lymphoma Analyst Views
Hodgkin's Lymphoma Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hodgkins-lymphoma-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
19 minutes ago
- CTV News
Maritime industries by increased U.S. tariffs
Atlantic Watch Many Maritime industries are feeling the pressure of increased U.S. tariffs on steel and aluminum.
Globe and Mail
24 minutes ago
- Globe and Mail
Constellation's Meta Deal: Why This Nuclear Stock is a Must Buy Now
Constellation Energy ( CEG ) and Meta signed a 20-year nuclear power deal on June 3. The power purchase agreement further solidifies the long-term growth relationship between nuclear energy and artificial intelligence, entrenching Constellation as one of the best long-term investments on Wall Street. Despite the blockbuster nuclear energy deal to fuel Meta's AI data center push—Constellation's second 20-year deal with an AI hyperscaler—the stock gave up all its early morning gains from Tuesday and fell again Wednesday morning. Constellation got rejected at its all-time highs after it grew overheated. Patient long-term investors and traders now have a chance to buy the nuclear energy powerhouse 13% below its highs, or wait for a possibly larger pullback to some of its moving averages. CEG Stock: Why The Nuclear Energy Giant is a Must Buy The U.S. government and big tech—two of the most critical drivers of the economy—have gone all in on nuclear energy. The U.S. government has launched various initiatives to support the revival of nuclear energy, aiming to triple capacity by 2050 to fuel economic growth and AI development and build greater energy independence. President Trump signed a nuclear energy executive order on May 23, designed to speed up nuclear power expansion and innovation. Meanwhile, Meta, Microsoft, Amazon, and other mega-cap technology companies have all signed nuclear energy deals with established companies and upstarts aiming to roll out the next generation of nuclear energy technology over the next decade. Big tech is helping drive the nuclear energy revolution because they are trying to use less fossil fuels while their AI expansion requires more energy than ever. Large data centers can consume nearly as much electricity as a midsize city, and generative AI platforms like ChatGPT use at least 10 times the energy of a typical Google search. Constellation is the largest U.S. nuclear power plant operator, managing over 20 reactors across roughly a dozen sites in the Midwest, Mid-Atlantic, and Northeast. CEG strengthened its nuclear energy bull case by securing a 20-year power purchase agreement with Microsoft ( MSFT ) in September that will see it restart Three Mile Island Unit 1. The biggest U.S. nuclear power company then cemented its position as a modern energy titan with its planned $26.6 billion deal to acquire natural gas and geothermal powerhouse Calpine at the start of 2025. CEG's acquisition creates the largest clean energy firm and expands its footprint into power-hungry, tech-heavy Texas and California. Most recently, Constellation and Meta ( META ) signed a 20-year power purchase agreement for nuclear power in Illinois set to start in 2027. 'The agreement supports the relicensing and continued operations of Constellation's high-performing Clinton nuclear facility for another two decades after the state's ratepayer funded zero emission credit (ZEC) program expires. This deal will expand Clinton's clean energy output by 30 megawatts through plant uprates.' The deal will also help Constellation pursue the possibility of building small modular nuclear reactors at the Illinois site. CEG raised its dividend by 10% in 2025 after it boosted its payout by 25% in 2024. Constellation also projects 'visible, double-digit long-term base EPS growth backed by the Nuclear Production Tax Credit.' The nuclear energy powerhouse is expected to grow its adjusted earnings by 9% in 2025 and 22% in 2026. CEG's EPS estimates have climbed significantly over the last few years, with its FY26 estimates up solidly since its early May earnings release. Buy Nuclear Energy Stock CEG on the Dip and Hold Forever? Constellation stock has soared 355% in the last three years to crush the Energy sector's 8% decline and the S&P 500's 50% run. The company's 470% surge since its early February 2022 IPO is more impressive, as Wall Street dove into the stock for dividend and earnings expansion and the long-term upside potential of nuclear energy. Image Source: Zacks Investment Research CEG has been on more of an up and down run over the past 12 months, yet it is still up 45%. The stock got rejected right at its all-time highs on Tuesday and trades roughly 13% below those levels. Long-term investors might want to buy Constellation now and avoid the market timing game (and buy more if fades to its 50-day). Traders, meanwhile, might wait for a possible slide to its early-January breakout levels (and its October highs) or other key moving averages. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Microsoft Corporation (MSFT): Free Stock Analysis Report Constellation Energy Corporation (CEG): Free Stock Analysis Report Meta Platforms, Inc. (META): Free Stock Analysis Report
Globe and Mail
an hour ago
- Globe and Mail
Ford Stock (NYSE:F) Rises With May Sales Numbers
When legacy automaker Ford (F) first revealed plans to supply all its customers with employee pricing, it was a bold move. A lot of people wondered how it would turn out. And the numbers for May suggest that it went pretty well indeed. Investors were certainly pleased with how it all boiled down, because they sent Ford shares up over 2% in Tuesday afternoon's trading. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter May 2025 brought with it a whopping 16.3% increase in sales against May 2024's numbers. These numbers were led by a 17.2% surge in sales of internal combustion vehicle models. Since these cars are usually the leaders in sales anyway, their surge allowed for a massive gain overall. This was vital, as Ford also posted a 25% drop in the sales of all its electric vehicles. Round things out with a 29% jump in hybrid car sales, and the picture was complete. Admittedly, some of those sales are likely customers front-loading, moving up purchases originally planned for later in the year to take advantage of the employee pricing. And with price hikes likely to come in the second half of the year, future sales may not be so productive. A Captivating Range Those hybrid vehicles are starting to catch a lot of notice, as one report noted that the range on the hybrid F-150 is proving more impressive than imagined. That report found that, despite driving in and around Seattle—which is pretty much a guarantee of stop-and-go urban driving—the vehicle still managed to get around 700 miles on a single tank of gasoline. It certainly helps that the F-150 in question got around 23 miles per gallon, which is respectable for a large-size truck. Throw in the fact the F-150 also has a wallet-busting 30.6 gallon tank—a fill-up for that one would run over $90 in many places—and the longevity of this vehicle becomes almost impossible. Plus, the tester in question reported that the battery life in the vehicle was more than sufficient to keep devices charged while traveling, especially with BlueCruise active. Is Ford Stock a Good Buy Right Now? Turning to Wall Street, analysts have a Hold consensus rating on F stock based on two Buys, 12 Holds and three Sells assigned in the past three months, as indicated by the graphic below. After a 17.04% loss in its share price over the past year, the average F price target of $9.71 per share implies 4.62% downside risk. See more F analyst ratings Disclosure
